Companies ›Healthcare ›2877.HK

2877.HK — HKEX Pharmaceuticals

China Shineway Pharmaceutical Group Ltd

HK$8,48

Open in Charts → Attach watcher ⌖

— —

HKD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

—

P/E

—

EV / Rev

—

Div yield

6,25 %

Op margin

40,7 %

ROE

11,8 %

Net margin

30,3 %

Debt / equity

0,04

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

—

Open

—

Next earnings

—

Ex-dividend

—

TR 1Y

—

About

China Shineway Pharmaceutical Group Ltd is a pharmaceutical company that develops, produces, and sells a range of pharmaceutical products, primarily in the Chinese market.

Business. China Shineway Pharmaceutical Group Ltd (2877.HK) is a pharmaceutical company engaged in the research, development, and sale of pharmaceutical products. The firm is headquartered in China and operates within the broader healthcare sector. It is primarily listed on the Hong Kong Stock Exchange. Specific details regarding operating segments or geographic revenue breakdowns are not available.

Classification92 %

SectorHealthcare

Business sectorPharmaceuticals & Medical Research

IndustryPharmaceuticals

ActivityPharmaceuticals & Medical Research

Generated · model-assisted

Sell-side consensus

HOLD1 analysts

0 buy1 hold0 sell

Avg 12m price target9,00

Analyst recommendations

1 analysts · consensus Hold

Buy0

Hold1

Sell0

12-month price target

9,00

Consensus of sell-side coverage.

Upcoming events

— missing data

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts→

Hold

1 analysts · indicative

Ownership

—

not yet wired

Profitability→

11,8 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning 2877.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to 2877.HK. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

China Shineway Pharmaceutical Group Ltd (2877.HK) is a pharmaceutical company engaged in the research, development, and sale of pharmaceutical products. The firm is headquartered in China and operates within the broader healthcare sector. It is primarily listed on the Hong Kong Stock Exchange. Specific details regarding operating segments or geographic revenue breakdowns are not available.

Classification92 %

SectorHealthcare

Business sectorPharmaceuticals & Medical Research

IndustryPharmaceuticals

ActivityPharmaceuticals & Medical Research

AI synthesis

GENERATED

China Shineway Pharmaceutical Group Ltd maintains a strong liquidity position, as evidenced by a current ratio of 3.71, indicating the company can cover its short-term liabilities more than three times over. The company's debt-to-equity ratio is 0.04, suggesting a conservative capital structure with minimal reliance on debt financing. However, the risk assessment notes that net cash is negative after subtracting total debt, signaling potential liquidity constraints.

In terms of profitability, the company's return on equity (ROE) is 11.78%, and return on assets (ROA) is 8.81%, both of which are strong indicators of efficient use of equity and assets. These figures suggest the company is generating solid returns relative to its capital base, though a direct comparison to industry medians is not available in the provided data.

The company's revenue is concentrated in a single business segment, as no segmental breakdown is provided in the input data. Geographically, the company is primarily focused on the Chinese market, with no disclosed international operations. This concentration may expose the company to regional economic and regulatory risks.

The company's growth trajectory is not explicitly outlined in the input data, but the absence of a detailed outlook suggests a stable or moderate growth path. Analysts have assigned a mean price target of 9.00 CNY, with a single "Hold" recommendation and no "Buy" or "Strong Buy" ratings, indicating a neutral outlook.

The risk assessment highlights a medium liquidity risk and a low dilution risk. The company's low dilution risk is supported by the absence of dilutive shares and no recent issuance activity. However, the negative net cash position raises concerns about short-term liquidity.

Recent events include the latest financial filing, which provides the most recent revenue and profitability figures. No additional filings or transcripts are available in the input data to provide further insight into the company's recent performance or strategic direction.

Key takeaways

China Shineway Pharmaceutical Group Ltd has a strong liquidity position with a current ratio of 3.71.
The company's ROE of 11.78% and ROA of 8.81% indicate efficient capital and asset utilization.
The company's revenue and operations are concentrated in a single segment and the Chinese market.
Analysts have assigned a neutral outlook with a mean price target of 9.00 CNY and a single "Hold" recommendation.
The company faces a medium liquidity risk due to a negative net cash position after subtracting total debt.
The company has a low dilution risk, with no dilutive shares and no recent issuance activity.

Bull / Bear case

Generated · model-assisted

— missing data

In focus — financials by report

Valuation

Market price

HK$8,48

Market cap

—

Enterprise valueⓘ

—

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

—

P / Tangible bookⓘ

—

Tangible book

HK$8.06B

Net cashⓘ

-HK$334.1M

Current ratioⓘ

3.7

Debt / equityⓘ

0.0

ROAⓘ

8.8%

ROEⓘ

11.8%

Cash conversionⓘ

—

CapEx / revenueⓘ

—

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

— missing data

Supply chain

— missing data

Peer comparison

— missing data

Market position

Stress test

— missing data

Predictor forecast

Next quarternear-term

Earnings · next quarterconf 45 %

EPS

Consensus EPS

1,26

Predicted surprise

+0,00

Beat probability

45 %

Analysts

Other metrics

Revenue

—

no estimate

Segment revenue

—

no estimate

Margin

—

no estimate

Segment margin

—

no estimate

as of 2026-05-21 · Earnings Surprise V1

Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.

Full fiscal year~1 year ahead

Full fiscal year · our forecast vs guidance vs consensus

Metric	Our forecast	Guidance	Consensus
EPS	—no estimate	—no estimate	1,26
Revenue	—no estimate	—no estimate	3,0B CNY
Operating income	—no estimate	—no estimate	989,5M CNY

Full-year consensus mean (period as reported by source) · consensus in CNY. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.

Probabilistic model output — not investment advice. · generated 2026-08-04

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Consensus distribution

sell-side coverage

Recommendation distribution1 analysts

Strong buy0

Buy0

Hold1

Sell0

Strong sell0

12-month price targetHK$9,00 · Median HK$9,00

Low HK$9,00High HK$9,00

Operating income · consensus989,5M CNY

EPS surprise

−0,4 %

reported vs consensus · miss

Revenue surprise

+3,3 %

reported vs consensus · beat

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

LowHK$9,00

MeanHK$9,00

MedianHK$9,00

HighHK$9,00

SpotHK$8,48

+6.1 %implied to mean12-month sell-side price targets · ▲ spot

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskMedium

Filing-based flags

Net cash is negative after subtracting total debt.

Benchmarks vs cohort

Op Margin40,7 %Best in class

Net Margin30,3 %Best in class

ROE11,8 %Above P75

D/E0,04Above median

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

— missing data

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Net Cash
cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
Return On Equity
net_income / total_equity
Debt To Equity
(short_term_debt + long_term_debt) / total_equity
Return On Assets
net_income / total_assets

Source documents

China Shineway Pharmaceutical Group Ltd Market data — financials · 2026-05-26
China Shineway Pharmaceutical Group Ltd Market data — analyst estimates · 2026-05-26
China Shineway Pharmaceutical Group Ltd Market data — ESG · 2026-05-26

Ownership & reference

Leadership

Zhenjiang LiExecutive Chairman of the Board

Insider activity

— missing data

Short positioning

— missing data

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

2877.HKCanonical

HKEX · HKD

Intel & risk

PredictorBeat prob45 %Surprise+0,00Full forecast →

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskMedium

Net cash is negative after subtracting total debt.

Evidence & claims

From filings & derived data

— missing data

The Thread

Everything we know, in order

2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)

The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

Analyst recommendations

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Consensus distribution

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Actions

Ask Handelsavisen

Ownership & reference

Leadership

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread